论文著作：
1. Hongjuan Yao, Lan Sun, Yan Liu, Jingcao Li, Xiaofei Zhou, Rui Li, Rongguang Shao, Yingge Zhang*, Liang Li*. The effect of targeting Gli1 siRNA nanoparticles on recurrence of gastric cancer guided by hyaluronic acid (HA) as an intrinsic ligand to CD44 receptor of cancer stem cells. International Journal of Nanomedicine (IF 5.115, Q1）. 2020, Sep 23; 15: 7013-7034.
2. Rui Cao, Wenping Song, Cheng Ye, Xiujun Liu, Liang Li, Yi Li, Hongjuan Yao, Xiaofei Zhou, Liang Li*, Rongguang Shao*. Internal enhancement of DNA damage by a novel bispecific antibody-drug conjugate-like therapeutics via blockage of mTOR and PD-L1 signal pathways in pancreatic cancer. Cancer Medicine（3.491, Q2）. 2019 Feb; 8(2):643-655.
3. Liang Li, Brooke L. Fridley, Gregory D. Jenkins, Krishna R. Kalari, Anthony Batzler, and Liewei Wang. Discovery of genetic biomarkers contributing to variation in drug response of cytidine analogues using human lymphoblastoid cell lines. BMC Genomics（3.986, Q2）. 2014 Feb 1;15: 93.
4. Liang Li, Brooke L. Fridley, Krishna R. Kalari, Gregory D. Jenkins, Anthony Batzler, Stephanie L. Safgren, Michelle A.T. Hildebrandt, Matthew M. Ames, Daniel J. Schaid and Liewei Wang. Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Research (9.727, Q1). 2008 Sep 1;68(17):7050-8.
5. Liang Li, Christopher S. Gondi, Dzung H. Dinh, and Jasti S. Rao. Transfection with anti-p65 intrabody suppresses invasion and angiogenesis in glioma cells by blocking NF-κB transcriptional activity. Clinical Cancer Research（IF 10.107, Q1). 2007 Apr 1;13(7):2178-90.
6. Huadong Pei, Liang Li, Brooke L. Fridley, Gregory D. Jenkins, Krishna R. Kalari, Wilma Lingle, Gloria Petersen, Zhenkun Lou and Liewei Wang. FKBP51 acts as a scaffolding protein to regulate Akt phosphorylation. Cancer Cell(IF 26.602, Q1）. 2009, 16(3): 259-266.
发明专利：
1. 姚红娟，李亮，宋文凭，周晓菲，李睿。一种靶向性核酸药物及其制备方法和用途。专利申请号：2019111166183 中国, 2019年11月15日.
2. 李亮，邵荣光，宋文凭，张诚玥，赵军阳，姚红娟，周晓菲，李睿，张燕。MBD4基因用于视网膜母细胞瘤预后和耐药诊断的用途。专利申请号：201910422932.8. 中国, 2019年05月22日.
3. 李亮，宋文凭，赵军阳，张诚玥，邵荣光，姚红娟，周晓菲，李睿，张燕。ARHGAP9基因用于视网膜母细胞瘤预后及耐药性诊断。专利申请号：201910671277. X. 中国, 2019年07月25日.
4. 李亮，邵荣光，叶程，曹睿，宋文凭，李良，李毅，刘秀均，甄永苏，赵春燕，姚红娟。双靶向配体化力达霉素DTLL联合吉西他滨在胰腺癌治疗中的作用。专利申请号：201711407833.X. 中国, 2017年12月25日.
5. 邵荣光，李亮，叶程，曹睿，宋文凭，李良，李毅，刘秀均，甄永苏，赵春燕. 双靶向配体化力达霉素DTLL的制备工艺改进和质量标准制定. 专利申请号：201711407843.3. 中国, 2017年12月25日.
6. Liewei Wang, Liang Li, Huadong Pei, Glorai Peterson, and Zhenkun Lou. Patent Application Title: FKBP5 (FKBP51) can function as a biomarker for prediction of response to gemcitabine, AraC, paclitaxel, docetaxel,SN38, etoposide as well as biomarker for tumorgenesis, USA, 11/06/2009, Patent Application No.: 61258720.
7. Liewei Wang, Richard Weinshilboum, Liang Li, Brooke Fridley, Krishna Kalari, Daniel Schaid, and Matthew M. Ames. Patent Application Title: Pharmacogenomic Cell Line Panel and Use Thereof, USA, Application Type: PCT, Pub. No.: 2011/0311606 A1.
8. Liang Li, Yong-su Zhen, Qingfang Miao, Boyang Shang, Xiujun Liu,Min Jiang. Intensified fusion protein Fv-LDP-AE having angiogenesis inhibiting and antitumor activity and the use thereof. China, 05/07/2008, International Application No.: PCT/CN2004/000842 (Application Type: PCT), Pub. No.: WO/2005/007701.
9. 李亮，甄永苏，苗庆芳，尚伯杨，刘秀均，江敏. 具有抑制血管生成及抗肿瘤作用的强化融合蛋白Fv-LDP-AE. 中国, ZL03150240.7, 2006年6月21日.
10. 甄永苏，王凤强，李亮. 力达霉素与单克隆抗体及其Fab＇片段的偶联物以及在结肠癌等肿瘤靶向治疗中的应用. 中国, ZL02153655.4，2006年6月8日.
11. 甄永苏，王凤强，李亮，刘秀均，尚伯杨. 治疗结肠癌等消化道肿瘤的抗IV型胶原酶单抗3D6与力达霉素的免疫偶联. 中国, ZL02125314，2003年1月8日.
李亮
北京市
研究领域：
生物医药
研究方向：
肿瘤个体化靶向治疗和临床转化医学研究
所在单位：
中国医学科学院北京协和医学院
